Phaseline

Companies › Kamau Therapeutics

Kamau Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
nula-cel
Gene correction therapy - autologous CD34+ hematopoietic stem cells with HbS to HbA gene c
–Phase 1Sickle Cell DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04819841nula-celPhase 1Sickle Cell DiseaseHematologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.